SUPERSTRING CAPITAL MANAGEMENT LP
Long book
$140.0M
Q1 2026
Positions
35
Top-10 weight
58%
concentration
Last quarter
+26.9%
SPY +14.8%
Turnover
67%
of book per quarter
Strategy in plain words
auto-generated from filingsSUPERSTRING CAPITAL MANAGEMENT LP is a concentrated fundamental stock-picker, specialised in healthcare (91% of the long book), running a $140.0M US long book across 35 positions.
The portfolio is concentrated: the top 10 names carry 58% of the portfolio. Turnover is high — positions rotate quickly, so individual names matter less than the process. Current anchor positions: SUMMIT THERAPEUTICS INC, IMMUNOVANT INC, COGENT BIOSCIENCES INC, SAVARA INC, UROGEN PHARMA LTD.
Over the last 9 quarters its long book ran on average 0.6pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-23.6%
Q2 2024
+3.8%
Q3 2024
-17.6%
Q4 2024
-12.4%
Q1 2025
+8.7%
Q2 2025
+37.5%
Q3 2025
+25.0%
Q4 2025
-2.6%
Q1 2026
+26.9%
Sector allocation
Healthcare 90%
Materials 10%
Long book by quarter
What does SUPERSTRING CAPITAL own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| SMMT SUMMIT THERAPEUTICS INC | Healthcare | 892.9K | $16.9M | 12.1% | New |
| IMVT IMMUNOVANT INC | Healthcare | 357.6K | $8.9M | 6.3% | +23.9% |
| COGT COGENT BIOSCIENCES INC | Healthcare | 225.2K | $8.7M | 6.2% | -38.5% |
| SVRA SAVARA INC | Healthcare | 1.6M | $8.7M | 6.2% | +59.3% |
| URGN UROGEN PHARMA LTD | Healthcare | 387.4K | $7.0M | 5.0% | -46.1% |
| DFTX DEFINIUM THERAPEUTICS INC | Materials | 351.5K | $6.6M | 4.7% | New |
| VIR VIR BIOTECHNOLOGY INC | Healthcare | 730.5K | $6.5M | 4.7% | New |
| PCVX VAXCYTE INC | Healthcare | 110.5K | $6.4M | 4.6% | New |
| CLDX CELLDEX THERAPEUTICS INC | Materials | 180.0K | $5.7M | 4.1% | +103.9% |
| SION SIONNA THERAPEUTICS INC | Healthcare | 141.0K | $5.7M | 4.0% | -21.9% |
| VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 11.0K | $4.9M | 3.5% | New |
| IQV IQVIA HOLDINGS INC | Healthcare | 25.7K | $4.4M | 3.1% | New |
| MPLT MAPLIGHT THERAPEUTICS INC | Healthcare | 192.1K | $3.9M | 2.8% | New |
| ARVN ARVINAS INC | Healthcare | 312.6K | $3.3M | 2.4% | New |
| ORKA ORUKA THERAPEUTICS INC | Healthcare | 63.6K | $3.1M | 2.2% | New |
| UTHR UNITED THERAPEUTICS CORP | Healthcare | 5.2K | $3.1M | 2.2% | -45.1% |
| TVTX TRAVERE THERAPEUTICS INC | Healthcare | 102.8K | $3.1M | 2.2% | +170.2% |
| TRVI TREVI THERAPEUTICS INC | Healthcare | 251.6K | $3.0M | 2.1% | +69.6% |
| CABA CABALETTA BIO INC | Healthcare | 1.1M | $2.9M | 2.0% | -52.7% |
| PFE PFIZER INC | Healthcare | 74.0K | $2.1M | 1.5% | New |
| AXSM AXSOME THERAPEUTICS INC | Healthcare | 11.2K | $1.9M | 1.4% | -70.0% |
| ORIC ORIC PHARMACEUTICALS INC | Healthcare | 115.2K | $1.5M | 1.0% | -54.9% |
| ACRS ACLARIS THERAPEUTICS INC | Healthcare | 366.5K | $1.4M | 1.0% | New |
| CLYM CLIMB BIO INC | Healthcare | 199.2K | $1.4M | 1.0% | New |
| TSHA TAYSHA GENE THERAPIES INC | Healthcare | 258.3K | $1.2M | 0.8% | -73.7% |
| DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 13.3K | $971K | 0.7% | -71.8% |
| TNXP TONIX PHARMACEUTICALS HOLDIN | Healthcare | 63.5K | $874K | 0.6% | New |
| CGEM CULLINAN THERAPEUTICS INC | Healthcare | 59.5K | $845K | 0.6% | New |
| TARA PROTARA THERAPEUTIC INC | Healthcare | 121.5K | $633K | 0.5% | -66.3% |
| PTN PALATIN TECHNOLOGIES INC | Healthcare | 36.0K | $627K | 0.4% | +5.9% |
| BMEA BIOMEA FUSION INC | Healthcare | 250.0K | $383K | 0.3% | Held |
| IPSC CENTURY THERAPEUTICS INC | Healthcare | 119.3K | $270K | 0.2% | -74.2% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 14, 2026 | 35 | $140.0M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 45 | $186.8M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 35 | $101.5M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 36 | $84.5M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 34 | $84.0M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 39 | $115.5M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 28 | $114.2M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 39 | $79.3M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 37 | $151.2M | canonical | SEC ↗ |